RecruitingNot ApplicableNCT07195071

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening


Sponsor

Columbia University

Enrollment

1,000 participants

Start Date

Feb 12, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Inclusion Criteria5

  • Age: 18 years - 55 years
  • Patients receiving obstetrical-related care at a CUMC-affiliated enrollment site
  • Patients who have elected to undergo OCS with the CUMC-affiliated obstetrics provider
  • Patients with prior OCS but planned to repeat OCS are eligible
  • Patients can speak and read in English or Spanish

Exclusion Criteria3

  • Patients who have previously completed a multigene hereditary cancer syndrome panel
  • Patients that have a hematologic cancer or hematologic pre-cancer
  • Patients who have a history of an autologous bone marrow transplant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENatera empower comprehensive hereditary cancer panel

Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers

DEVICEObstetrical carrier screening

Obstetrical carrier screening for genetic conditions


Locations(1)

Columbia University Irving Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07195071


Related Trials